GeneDx Holdings Corp. Form 4 Filings

GeneDx Holdings Corp. (WGS) reported that Chief Financial Officer Kevin Feeley settled 2,462 Restricted Stock Units into an equal number of shares of Class A Common Stock on September 9, 2026. On the same day, he sold 1,285 shares in a sell-to-cover transaction at a weighted average price of $84.2179 per share to satisfy tax withholding obligations, which the company states was not a discretionary trade. Following this sale, he beneficially owned 41,476 shares of Class A Common Stock and held RSUs for up to 78,864 shares and options for up to 25,906 shares, all vesting according to their terms.

GeneDx Holdings Corp. (WGS) reported that its Chief Financial Officer, Kevin Feeley, settled 717 Restricted Stock Units into 717 shares of Class A Common Stock on September 1, 2026, for no cash consideration. On the same date, 372 of those shares were sold at a weighted average price of $83.839 per share solely to satisfy tax withholding obligations in a non-discretionary “sell to cover” transaction. After these events, Feeley beneficially owned 40,299 shares of Class A Common Stock, RSUs for up to 81,326 additional shares, and options for up to 25,906 shares, all vesting according to their existing terms.

GeneDx Holdings Corp.'s President, Mark A. Gardner, received a grant of 35,441 restricted stock units (RSUs) tied to the company’s Class A common stock. Each RSU converts into one share for no cash payment when it settles, making this a compensation award rather than a market purchase.

The award vests in stages, with 25% of the RSUs vesting each July 1, starting on July 1, 2027, as long as Gardner continues serving the company through each vesting date. After this grant, his reported derivative holdings from this award total 35,441 underlying shares.

GeneDx Holdings Corp. director Jason Ryan reported an equity award vesting and related share movements. He exercised 3,576 restricted stock units into 3,576 shares of Class A common stock at no cost, increasing his direct holdings to 15,480 shares. He also reports indirect ownership of 103,284 shares held by the Jason Ryan 2024 GRAT, where he serves as trustee and sole annuitant. The RSUs represent a right to receive one share each upon settlement, with vesting tied to the 2026 annual shareholder meeting or the first anniversary of the grant date, subject to continued service.

GeneDx Holdings director Joshua Ruch reported equity-based compensation activity and updated holdings in Class A Common Stock. He exercised previously awarded restricted stock units (RSUs) covering 3,576 shares at no cost, increasing his directly held common stock to 33,299 shares.

He also received a new grant of 4,248 RSUs, each representing a right to receive one share of Class A Common Stock for no consideration. This award vests on the earlier of the 2027 annual stockholders’ meeting or the first anniversary of the grant date, subject to continued service. Entities associated with him hold additional indirect positions in GeneDx shares, for which he may be deemed to share voting and investment discretion, while disclaiming beneficial ownership beyond any pecuniary interest.

GeneDx Holdings Corp. director Richard C. Pfenniger Jr. reported equity compensation changes involving Class A Common Stock and restricted stock units. He exercised 3,576 restricted stock units into the same number of Class A shares, increasing his direct holdings to 45,082 shares after the transaction.

On the same date, he received a new grant of 4,248 restricted stock units, each representing a right to one share of Class A Common Stock for no cash consideration. According to the terms, the new RSU award vests in full on the earlier of the 2027 annual stockholders’ meeting or the first anniversary of the grant date, subject to continued service.

GeneDx Holdings Corp. director and 10% owner Keith A. Meister reported equity compensation activity involving Class A Common Stock and restricted stock units. On June 18, 2026, 3,576 RSUs were exercised, converting into 3,576 shares of Class A Common Stock, bringing his direct holdings of this stock to 23,705 shares.

On the same date, he received a new grant of 4,248 restricted stock units, each representing one share of Class A Common Stock upon settlement for no consideration. This award vests on the earlier of the 2027 annual stockholder meeting or the first anniversary of the grant date, subject to continued service. Separate from these grants, investment funds advised by Corvex Management LP hold 333,144 shares, and CMLS Holdings LLC holds 4,784,570 shares, over which Meister shares or may be deemed to share investment discretion.

GeneDx Holdings Corp. director Emily M. Leproust increased her equity stake through routine stock-based compensation. On June 18, 2026, she exercised 3,576 Restricted Stock Units (RSUs), receiving the same number of shares of Class A Common Stock for no cash consideration, bringing her direct holdings to 24,852 shares.

She also received a new grant of 4,248 RSUs, each representing a contingent right to one share of Class A Common Stock upon settlement. According to the award terms, this grant vests on the earlier of the 2027 annual stockholder meeting or the first anniversary of the grant date, subject to her continued service.

Fuchs Thomas reported acquisition or exercise transactions in this Form 4 filing.

GeneDx Holdings Corp. director Thomas Fuchs received an equity compensation award in the form of 4,248 restricted stock units on June 18, 2026. Each RSU represents a contingent right to receive one share of Class A common stock upon settlement for no cash payment.

The entire award will vest on the earlier of the company’s 2027 annual stockholder meeting or the first anniversary of the grant date, as long as Fuchs continues to serve the company through that date. If service ends before vesting, the units may be cancelled rather than vest. Following this grant, Fuchs is reported as holding 4,248 RSUs, and no open‑market purchases or sales are disclosed in this filing.

GeneDx Holdings Corp. director and 10% owner Eli Casdin reported equity compensation activity involving GeneDx Class A Common Stock and restricted stock units. He exercised 3,576 RSUs into 3,576 shares of Class A Common Stock at no cost, increasing his direct common share holdings to 24,093 shares.

Casdin also received a new grant of 4,248 RSUs, each representing one future share of Class A Common Stock, which will vest on the earlier of the 2027 annual stockholder meeting or the first anniversary of the grant date, subject to continued service. In addition, entities associated with Casdin hold substantial indirect positions, including 3,707,164 shares through Casdin Partners Master Fund, LP, 333,144 shares through CMLS Holdings LLC, and 19,247 shares through Casdin Partners GP, LLC.

GeneDx Holdings Corp. chief financial officer Kevin Feeley reported an RSU vesting and related share sales to cover taxes. On June 16, 2026, 7,197 restricted stock units converted into an equal number of Class A Common shares for no cash consideration.

To fund tax withholding on this vesting, he sold a total of 3,729 Class A Common shares in open-market transactions at weighted-average prices between about $59 and $62 per share. After these sales, he beneficially owned 39,954 shares, plus RSUs covering up to 82,043 shares and options for up to 25,906 shares, all vesting under their existing terms.

GeneDx Holdings Corp. CEO Katherine Stueland reported routine equity compensation activity and related tax sales. On June 16, 2026, she exercised restricted stock units, acquiring 18,750 shares of Class A Common Stock upon RSU vesting.

On the same date she sold a total of 10,501 shares of Class A Common Stock in open-market transactions at weighted average prices around $59.75–$61.50 per share to cover tax withholding obligations from the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, she beneficially owned 104,372 shares of Class A Common Stock, plus RSUs for up to 305,525 shares and options for up to 107,610 shares that vest under their terms.

GeneDx Holdings Corp. chief financial officer Kevin Feeley reported RSU vesting and a related tax sale of common stock. On June 9, 2026, restricted stock units converted into 2,462 shares of Class A Common Stock for no cash consideration. On the same date, he sold 1,266 shares of Class A Common Stock at $53.77 per share in an open-market transaction to cover tax withholding obligations, described as a non-discretionary “sell to cover” event. After these transactions, he beneficially owned 36,486 shares of Class A Common Stock, as well as RSUs representing up to 89,240 additional shares and options to purchase up to 25,906 shares, which vest according to their terms. The RSUs vest in 6.25% quarterly installments, contingent on continued service.

GeneDx Holdings CEO Katherine Stueland exercised restricted stock units that converted into 6,546 shares of Class A Common Stock and sold 3,639 shares at about $53.77 per share. The sale was a “sell to cover” transaction to satisfy tax withholding obligations and was not discretionary. After these transactions, she beneficially owned 96,123 shares of common stock, RSUs for up to 324,275 additional shares, and options to purchase up to 107,610 shares that vest over time.

GeneDx Holdings Corp. reported an insider-related increase in holdings by entities associated with Casdin Capital. Casdin Partners Master Fund, L.P. made open-market purchases of 150,000 Class A common shares at $56.4449 per share on June 4, 2026 and 50,000 shares at $52.8566 per share on June 5, 2026, totaling 200,000 shares. After these trades, the Master Fund held 3,707,164 shares indirectly. Additional positions as of June 4, 2026 included 333,144 shares owned by the Master Fund, 19,247 shares owned by the GP entity, and 20,517 shares owned directly by Eli Casdin, each as separate holdings.

GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported routine equity compensation activity involving restricted stock units (RSUs) and a tax-related share sale. On June 1, 2026, 717 RSUs converted into the same number of Class A Common shares for no cash cost, reflecting vesting of previously granted awards.

On the same date, Feeley sold 369 shares of Class A Common Stock at $51.74 per share in an open-market transaction solely to cover tax withholding obligations from the RSU vesting, described as a “sell to cover” and not a discretionary trade. After these transactions, he beneficially owned 35,290 shares of Class A Common Stock, plus RSUs representing up to 91,702 additional shares and options to purchase up to 25,906 shares, all subject to their vesting schedules.

GeneDx Holdings Corp. reported that investment entities associated with Casdin Capital made open-market purchases of a total of 500,000 shares of Class A Common Stock. These buys occurred on May 18–20, 2026 at weighted average prices in the low-to-mid $40 range.

After these transactions, an investment fund managed by Casdin Capital reported holding 3,507,164 shares indirectly. Separate positions include 20,517 shares owned directly by Eli Casdin and other indirect holdings of 333,144 and 19,247 shares reported for related entities.

GeneDx Holdings Corp. reported substantial insider-related buying of its Class A Common Stock by investment funds advised by Corvex Management LP. These funds purchased a total of 351,273 shares in open-market transactions between May 13 and May 15 at weighted average prices within ranges from about $37.78 to $40.60 per share.

After these transactions, the Corvex-advised funds directly hold 4,784,570 shares. In addition, CMLS Holdings LLC holds 333,144 shares, over which Keith A. Meister shares voting and investment discretion, and Meister separately holds 20,129 shares issued upon vesting of restricted stock units for his board service.

GeneDx Holdings Corp. reported significant insider buying linked to director and ten percent owner Keith A. Meister. Investment funds advised by Corvex Management LP made open-market purchases totaling 1,205,147 shares of Class A Common Stock between May 7 and May 11, 2026, at weighted average prices generally in the mid-$30s to low-$40s per share. After these trades, the Corvex-advised funds directly held 4,433,297 shares of Class A Common Stock. The filing states Mr. Meister may be deemed to indirectly beneficially own these shares through his control of Corvex’s general partner, while both Corvex and Mr. Meister disclaim beneficial ownership beyond their pecuniary interest. The filing also notes 333,144 shares held of record by CMLS Holdings LLC, where Mr. Meister shares voting and investment discretion, and 20,129 shares issued to Mr. Meister upon vesting of restricted stock units for his board service.

GeneDx Holdings Corp. reported new derivative activity by Casdin-affiliated entities. Casdin Partners Master Fund, L.P. entered into open-market purchases of cash-settled swap agreements referencing GeneDx Class A common stock on three dates. On May 7, 2026, the Master Fund added swaps representing economic exposure to 500,000 notional shares at $38.1543 per share. On May 8, 2026, it added exposure to a further 300,000 notional shares at $41.0261 per share, and on May 11, 2026, to 50,000 notional shares at $39.6602 per share. After these transactions, the filing shows aggregate exposure of 850,000 notional shares through cash-settled swaps. The footnotes state these swaps provide economic results comparable to ownership but do not give the Master Fund voting or disposition power over GeneDx shares, and that the swaps are owned directly by the Master Fund and may be deemed indirectly beneficially owned by Casdin Capital, LLC, Casdin Partners GP, LLC, and Eli Casdin.

GeneDx Holdings Corp. chief executive officer Katherine Stueland reported routine equity compensation activity involving restricted stock units and related tax sales. On April 29, 2026, 3,874 restricted stock units converted into the same number of shares of Class A Common Stock for no cash consideration, increasing her direct holdings.

The filing also shows open-market sales totaling 2,172 shares of Class A Common Stock at prices around the mid‑$60s per share to cover tax withholding obligations from the RSU vesting. A footnote states this was a “sell to cover” transaction and “does not represent a discretionary transaction.” Following these sales, she beneficially owned 93,216 shares of Class A Common Stock, plus RSUs for up to 330,821 additional shares and options to purchase up to 107,610 shares, all vesting under their existing schedules.

GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity. On April 29, 2026, 754 restricted stock units converted into Class A Common Stock, and 392 shares were sold in an open-market transaction to cover tax withholding obligations under a non-discretionary "sell to cover" arrangement. Following these transactions, he beneficially owned 34,942 shares of Class A Common Stock, plus RSUs representing contingent rights to receive up to 92,419 additional shares and options to purchase up to 25,906 shares, all vesting according to their respective schedules.

GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity. He exercised 16,250 restricted stock units, receiving the same number of Class A Common Stock shares for no cash cost. On the same date, he sold 8,818 shares of Class A Common Stock in several open-market transactions at weighted average prices in the low-to-mid $60s per share. According to the disclosure, these sales were executed solely to cover tax withholding obligations from the RSU vesting under a “sell to cover” arrangement and were not discretionary trades. After these transactions, he beneficially owned 34,580 shares of Class A Common Stock, plus RSUs representing contingent rights to receive up to 93,173 additional shares and options to purchase up to 25,906 shares, all vesting over time according to their terms.

GeneDx Holdings Corp. CEO Katherine Stueland exercised 80,000 restricted stock units into Class A common stock and had 46,933 shares sold to cover tax withholding obligations. The sales were executed as non-discretionary “sell to cover” transactions at weighted average prices between approximately $60.93 and $65.61 per share.

After these transactions, she beneficially owned 91,514 shares of Class A common stock and also held restricted stock units representing contingent rights to receive up to 334,695 additional shares, plus options to purchase up to 107,610 shares that vest according to their terms.

GeneDx Holdings Corp.'s chief executive officer Katherine Stueland reported routine equity compensation activity involving restricted stock units and related tax sales. She exercised RSUs covering 30,671 shares of Class A Common Stock at no cost as tranches vested on March 15–16. To cover tax withholding obligations from these vestings, she sold 17,179 shares in open-market transactions at weighted average prices in ranges around $75.74 to $78.16 per share pursuant to a sell-to-cover arrangement, which the filing notes was not a discretionary transaction. Following these tax-related sales, she directly owned 58,447 shares of Class A Common Stock and held RSUs representing up to 414,695 additional shares and options to purchase 107,610 shares, all vesting according to their existing terms.

GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported routine equity compensation activity. On March 15–16, 2026, he exercised restricted stock units that converted into a total of 11,012 shares of Class A Common Stock at no cost.

On March 16, he then sold 5,706 shares of Class A Common Stock in multiple open-market transactions at weighted average prices in the mid‑$70s. According to the disclosure, these sales were made solely to cover tax withholding obligations under a “sell to cover” arrangement and were not discretionary.

After these transactions, Feeley beneficially owned 27,148 shares of Class A Common Stock and also held RSUs for up to 109,423 shares and options for up to 25,906 shares, all vesting according to their existing schedules.

GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity. On March 9, 2026, he exercised restricted stock units for 2,462 shares of Class A common stock at no cost, converting RSUs into shares. He then sold 1,280 shares at a weighted average price of $86.754 per share in a "sell to cover" transaction to satisfy tax withholding obligations, which the footnotes state was not a discretionary trade. Following these moves, he directly owned 21,842 shares of Class A common stock and also held RSUs covering up to 120,435 additional shares and options for up to 25,906 shares, all vesting under their existing schedules.

GeneDx Holdings Corp. CEO Katherine Stueland reported routine equity compensation activity. She exercised restricted stock units into 6,546 shares of Class A Common Stock at no cost, then sold 3,678 of those shares at a weighted average price of $86.748 per share solely to cover tax withholding obligations via a “sell to cover” transaction, which the filing states was not discretionary.

After these transactions, she directly owned 44,955 shares of Class A Common Stock. The filing also notes additional unvested awards: RSUs representing contingent rights to receive up to 445,366 shares and options to purchase up to 107,610 shares, which vest over time according to their terms.

GeneDx Holdings Corp. chief financial officer Kevin Feeley acquired additional company stock in an insider transaction. On March 6, 2026, he obtained 1,986 shares of GeneDx Class A common stock directly from the company at $88.11 per share under a subscription agreement exempt under Rule 16b-3(d). After this award, his direct ownership increased to 20,660 shares of Class A common stock.

GeneDx Holdings Corp. reported that Chief Executive Officer Katherine Stueland acquired additional company stock. On March 6, 2026, she obtained 3,404 shares of GeneDx Class A common stock directly from the company in an exempt transaction at $88.11 per share, based on that day’s closing price.

Following this acquisition, Stueland directly holds 42,087 shares of GeneDx Class A common stock. The transaction was executed under a Subscription Agreement between GeneDx and Stueland and was structured to qualify for exemption under Rule 16b-3(d).

GeneDx Holdings Corp. reported that investment funds advised by Corvex Management LP, with Keith A. Meister as a control person, made open-market purchases of a total of 169,521 shares of Class A common stock on March 3 and March 5 at prices generally ranging from about $70 to $82 per share.

After these trades, investment funds advised by Corvex directly held 3,228,150 GeneDx Class A shares. CMLS Holdings LLC held 333,144 shares, over which Mr. Meister shares voting and investment discretion, and Mr. Meister’s beneficial holdings also include 20,129 shares issued upon vesting of restricted stock units for his board service. Corvex and Mr. Meister each disclaim beneficial ownership except to the extent of their pecuniary interest.

GeneDx Holdings Corp. reported that Chief Operating Officer Bryan Dechairo acquired 10,430 restricted stock units (RSUs) as an equity award. Each RSU represents a contingent right to receive one share of Class A common stock for no cash consideration upon settlement.

The award vests over time, with 25% of the RSUs vesting each year on the anniversary of the grant date. The first tranche is scheduled to vest on April 1, 2027, provided Dechairo continues to serve the company on each vesting date. The RSUs have no expiration; they either vest or are cancelled before vesting.

GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported a mix of equity awards and share sales. On March 3, 2026, he acquired 15,262 shares of Class A Common Stock and 10,865 RSUs at no cost in connection with a performance-based restricted stock unit award tied to revenue and adjusted net income.

On March 4, 2026, he sold a total of 6,187 shares of Class A Common Stock in open-market transactions at weighted average prices in the high-$70 range to cover tax withholding obligations from that vesting. After these transactions, he beneficially owned 18,674 shares, plus RSUs for up to 122,897 shares and options for up to 25,906 shares, subject to vesting.

GeneDx Holdings Corp. chief executive officer Katherine Stueland reported a mix of equity awards and related share sales. On March 3, 2026, she acquired 47,684 shares of Class A Common Stock and 40,418 restricted stock units as a grant tied to a 2025 performance-based award.

On March 4, 2026, she sold a total of 25,459 shares of Class A Common Stock in open-market transactions at weighted average prices between about $77 and $79.64 per share to cover tax withholding obligations from the award’s vesting. After these transactions, she directly owned 38,683 shares, plus RSUs for up to 451,912 shares and options for up to 107,610 shares, all subject to their vesting terms.

GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported both an RSU vesting and a small tax-related stock sale. On March 1, 2026, 718 restricted stock units were settled, converting into 718 shares of Class A common stock for no cash cost.

On March 2, 2026, Feeley sold 287 Class A shares in an open-market transaction solely to cover tax withholding from the RSU vesting, at a weighted average price of $77.5187 per share, with individual trades ranging from $76.99 to $77.53. After these transactions, he beneficially owned 9,599 Class A shares, RSUs representing up to 112,032 additional shares, and options to purchase up to 25,906 shares, which vest quarterly at 6.25% of the total award.

GeneDx Holdings Corp.'s Chief Operating Officer, Dechairo Bryan, reported multiple open‑market sales of Class A Common Stock on February 4, 2026 under a pre‑arranged Rule 10b5‑1 trading plan adopted on September 15, 2025.

The transactions totaled 5,961 shares sold at weighted average prices ranging from $83.0352 to $91.92 per share, reducing his directly held Class A Common Stock to zero. After these sales, he beneficially owned RSUs covering contingent rights to receive up to 28,123 shares of Class A Common Stock, vesting according to their terms.

GeneDx Holdings Corp. Chief Operating Officer Bryan Dechairo reported RSU vesting and related share sales. On February 1, 2026, 9,374 restricted stock units converted into an equal number of Class A Common shares at $0 per share upon vesting. On February 2, 2026, he sold a total of 3,413 shares in multiple transactions at weighted average prices between $96.7676 and $100.3146 per share to cover tax withholding obligations under a “sell to cover” arrangement, described as non-discretionary. Following these transactions, he directly beneficially owned 5,961 shares of Class A Common Stock and RSUs representing contingent rights to receive up to 28,123 additional shares, vesting over time subject to continued service.

GeneDx Holdings Corp. chief financial officer Kevin Feeley reported routine equity compensation activity involving restricted stock units (RSUs) and related share sales. On January 29, 2026, 754 RSUs converted into the same number of Class A Common shares for no cash consideration.

On the same date, Feeley sold 315 shares at $94 and 2 shares at $92.0601. The company states these sales were made solely to cover tax withholding obligations through a “sell to cover” arrangement and were not discretionary trades. After these transactions, Feeley directly held 9,168 Class A Common shares, plus RSUs representing up to 112,750 shares and options for up to 25,906 shares, all vesting according to their existing schedules.

GeneDx Holdings Corp.'s chief executive officer Katherine Stueland reported routine equity activity tied to restricted stock units. On January 29, 2026 she settled 3,874 RSUs into the same number of Class A common shares for no cash cost, then sold 1,653 shares at a weighted average price of $93.9957 to cover tax withholding obligations through a non‑discretionary “sell to cover” transaction. After these moves she directly owned 16,458 Class A shares, along with RSUs representing contingent rights to receive up to 411,494 additional shares and options to purchase up to 107,610 shares, which vest according to their existing schedules.

GeneDx Holdings Corp. Chief Financial Officer insider transaction shows routine equity compensation activity. On December 16, 2025, the CFO exercised 7,197 restricted stock units (RSUs), receiving the same number of Class A common shares for no cash consideration. On the same date, multiple small blocks of Class A common stock were sold at weighted average prices between $138.93 and $150.75 per share.

According to the disclosure, these sales were made solely to cover tax withholding obligations arising from the RSU vesting under a “sell to cover” arrangement and were not discretionary trades by the executive. After these transactions, the CFO beneficially owned 8,731 shares of Class A common stock, as well as RSUs representing contingent rights to receive up to 113,504 shares and options to purchase up to 25,906 shares of Class A common stock, all vesting according to their existing terms.

GeneDx Holdings Corp.’s chief executive officer and director reported routine equity transactions involving Class A Common Stock on December 16, 2025. The filing shows 18,750 restricted stock units converting into the same number of shares at an exercise price of $0, increasing the executive’s directly held stock before related sales.

On the same date, the executive sold multiple small blocks of shares at weighted average prices reported between $138.93 and $150.75. According to the notes, these trades were made solely to cover tax withholding obligations tied to the RSU vesting and were not discretionary sales. After these transactions, the executive directly owned 14,237 shares of Class A Common Stock, plus RSUs representing up to 415,368 shares and options to purchase up to 107,610 shares, all vesting over time under their existing award terms.

GeneDx Holdings Corp. reported that its chief financial officer completed an equity award transaction involving Class A Common Stock on 12/09/2025. The filing shows 2,462 restricted stock units were converted into an equal number of shares at $0 exercise price, reflecting the vesting of previously granted RSUs.

To cover tax withholding triggered by this vesting, the officer sold 1,266 shares at $159.28 per share in a "sell to cover" transaction, described as non-discretionary. After these transactions, the officer beneficially owned 5,389 shares of Class A Common Stock, along with RSUs representing up to 120,701 additional shares and options for up to 25,906 shares, all subject to their vesting terms.

GeneDx Holdings Corp. (WGS) director reports insider share sales. A reporting person serving as a director filed a Form 4 for multiple sales of GeneDx Class A common stock on 11/24/2025. The trades were executed indirectly through investment entities Kariba LLC, Rugu2 LLC and VAAL Investment Partners Q9 LP, where the director has voting and investment power.

The sales occurred in several blocks at weighted average prices ranging from about $157.80 to $162.175 per share, with each block reported separately. After the reported transactions, the filing shows continued indirect beneficial ownership of GeneDx Class A shares by each of the three entities. The director disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.

GeneDx Holdings (WGS) CEO and director reported an RSU settlement and related tax-withholding sales. On 10/29/2025, 3,874 shares of Class A Common Stock were acquired upon RSU vesting at $0 (code M), and 2,154 shares and 4 shares were sold at $136.54 and $136.75, respectively (code S), to cover tax obligations.

After these transactions, the reporting person held 3,436 Class A shares directly. In addition, they held RSUs representing up to 440,665 shares and options for up to 107,610 shares, which vest according to their terms. The RSU award vested 25% on April 29, 2023 and April 29, 2024, and 6.25% on each quarterly anniversary thereafter, with the last tranche scheduled for April 29, 2026.

GeneDx Holdings (WGS) CFO reported routine equity activity. On 10/29/2025, 753 restricted stock units settled into Class A shares at $0, and 388 shares were sold at $136.54 to cover tax withholding tied to the RSU vesting.

After these transactions, the reporting person beneficially owned 3,757 Class A shares. They also held RSUs representing up to 123,880 shares and options to purchase up to 25,906 shares, which vest according to their terms.

The RSU vesting schedule states 25% vested on April 29, 2023 and April 29, 2024, with an additional 6.25% vesting each quarterly anniversary thereafter, with the final tranche scheduled for April 29, 2026.

Keith A. Meister, a director and reported 10% owner, amended a Form 4 to correct previously misstated holdings in GeneDx Holdings Corp. (WGS). The amendment clarifies that investment funds advised by Corvex Management LP hold 2,473,781 shares of Class A common stock and that CMLS Holdings LLC holds 333,144 shares, for an aggregate indirect beneficial ownership of 2,806,925 shares. The filing states Mr. Meister may be deemed to indirectly own these shares through his control or board role but disclaims direct beneficial ownership except for any pecuniary interest. The amendment notes the corrected figures reflect a 1-for-33 reverse stock split effective May 4, 2023.

Katherine Stueland, Chief Executive Officer and a director of GeneDx Holdings Corp. (WGS), reported multiple sales of Class A common stock on 09/30/2025 under a preexisting Rule 10b5-1 trading plan adopted August 16, 2024. The Form 4 shows eight separate sale entries that together reduced her direct beneficial holdings from 13,972 shares to 1,720 shares held directly after the transactions. Reported weighted-average prices for the sales ranged from about $104.98 to $112.04 per share.

The filing discloses that, in addition to the 1,720 directly held shares, Ms. Stueland beneficially owns restricted stock units convertible into up to 444,539 shares and options to purchase up to 107,610 shares that vest according to their terms. The transactions were executed pursuant to the 10b5-1 plan and the Form 4 was signed by an attorney-in-fact on 10/01/2025.

GeneDx Holdings Corp. Chief Financial Officer Kevin Feeley reported multiple transactions in the company’s Class A common stock on 09/30/2025. Mr. Feeley acquired 1,246 shares via exercise of employee stock options at an exercise price of $32.67 and sold a series of shares in multiple transactions under a Rule 10b5-1 trading plan adopted August 21, 2024. The reported sales totaled 7,609 shares across weighted-average prices ranging from about $104.98 to $113.68, leaving the reporting person with 3,392 shares beneficially owned. The filing discloses outstanding RSUs for up to 124,633 shares and options for up to 25,906 shares that vest over time.